PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs. Intensive Chemo if fit patients with AML.
Daraxonrasib looks like a promising drug for RAS-mutant NSCLC, too.
Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm
Fler avsnitt från "OncoPharm"



Missa inte ett avsnitt av “OncoPharm” och prenumerera på det i GetPodcast-appen.








